BENZIMIDAZOLPROLINDERIVATE

European patent · EP2855453 · In force

Register entry

Publication number
EP2855453
Application number
EP13744805
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Jun 3, 2013
Published
Apr 8, 2015
Granted
Dec 7, 2016
Protection ends at the latest
Jun 2, 2033
Next annual fee due
Jun 30, 2027
IPC classes
C07D 403/14 (2006.01)
C07D 401/14 (2006.01)
C07D 403/04 (2006.01)
C07D 417/14 (2006.01)
Priority
EP 12170748 04.06.2012
EP 13158520 11.03.2013
PCT application
PCT/IB2013/054567 03.06.2013
PCT publication
WO2013/182972 12.12.2013
Filing language
English
Source
Swissreg

Supplementary protection certificates

A certificate extends the patent’s protection for a medicine or a plant protection product authorised in Switzerland.

Daridorexantum

C02855453/01 · Medicine · Granted · Protection from Jun 3, 2033 to Nov 30, 2037

Authorisation 68481 (Swissmedic, Dec 1, 2022)

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Jul 1, 2026

    Next annual fee due on

    Next annual fee due on
    30.06.2026 → 30.06.2027

    Published in Swissreg on 01.07.2026

  2. Jul 1, 2026

    Pledge entered

    Pledgee
    BioPharma Credit PLC, 19th Floor 51 Lime Street, London, United Kingdom, EC3M 7DQ, United Kingdom

    Published in Swissreg on 01.07.2026

  3. Jul 1, 2025

    Next annual fee due on

    Next annual fee due on
    30.06.2025 → 30.06.2026

    Published in Swissreg on 01.07.2025

  4. Nov 25, 2024

    Licensee entered

    License holder
    Nxera Pharma Japan Co., Ltd., 9-7-2 Akasaka Minato-ku, 107-0052 Tokyo, Japan

    Published in Swissreg on 25.11.2024

  5. Jul 1, 2024

    Change

    Published in Swissreg on 01.07.2024

  6. Jul 1, 2023

    Change

    Published in Swissreg on 01.07.2023

  7. Jul 1, 2022

    Change

    Published in Swissreg on 01.07.2022

  8. Sep 14, 2017

    Transferred

    Owner
    Actelion Pharmaceuticals Ltd., Gewerbestrasse 16, 4123 Allschwil → Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, 4123 Allschwil

    Published in Swissreg on 14.09.2017

1 earlier entry
  1. Dec 7, 2016

    Granted

    Published in Swissreg on 07.12.2016

Parties

Holder

Idorsia Pharmaceuticals Ltd

Hegenheimermattweg 91, 4123 Allschwil

Inventor

BOSS, Christoph

4123 Allschwil

BROTSCHI, Christine

4123 Allschwil

GUDE, Markus

4123 Allschwil

HEIDMANN, Bibia

4123 Allschwil

SIFFERLEN, Thierry

4123 Allschwil

WILLIAMS, Jodi T.

4123 Allschwil

Licensee

Nxera Pharma Japan Co., Ltd.

9-7-2 Akasaka Minato-ku, 107-0052 Tokyo, JP

Pledgee

BioPharma Credit PLC

19th Floor 51 Lime Street, London, United Kingdom, EC3M 7DQ, GB

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.